A single substitution at AA14 in the GRPR radiotracer 68Ga Ga-DOTA-Pip-PEP-4 produced 68Ga Ga-SP01011, which reached 9.63 %ID/g tumor uptake while pancreas uptake fell from 24.8 %ID/g for the parent to below 5 %ID/g in mice. The three derivatives reported in Nuclear Medicine and Biology show how…
A single substitution at position AA14 in the gastrin-releasing peptide receptor GRPR radiotracer 68Ga Ga-DOTA-Pip-PEP-4 has produced a derivative with higher tumor uptake and far lower pancreatic background. The compound, 68Ga Ga-SP01011 , reached 9.63 ± 1.07%ID/g in PC-3 tumor xenografts at 1 h post-injection, while the three derivatives tested in the study held pancreas uptake between 0.83 and 4.96%ID/g. That is a sharp contrast with the parent tracer, whose pancreas uptake was 24.8 ± 1.77%ID/g.
The work, published in the journal Nuclear Medicine and Biology, replaced the piperidine moiety at AA14 of 68Ga Ga-DOTA-Pip-PEP-4 with six-membered ring-containing derivatives, producing three new tracers: SP01010 , SP01011 , and SP01022 . The parent compound was already known for favorable tumor uptake, but its pronounced pancreas retention limited its appeal. All three replacements markedly reduced pancreas uptake, and one of them, 68Ga Ga-SP01011, also improved tumor uptake.
The result is a compact demonstration that the residue at a single position in a peptide scaffold can push receptor affinity, tumor retention, and off-target organ accumulation in different directions at once. 68Ga Ga-SP01011 now sits at the top of this series on the axes that matter most for imaging: the strongest binding affinity, the highest tumor uptake, and minimal pancreatic background. That combination was achieved by changing one residue while leaving the DOTA chelator and the 68Ga radiometal untouched, which makes the substitution a useful handle for further design.
The three derivatives were assembled by solid-phase synthesis in 39-51% yield, and their nonradioactive gallium-complexed standards were obtained in 69-82% yield. The standards served two roles: they provided reference material for the radiolabeled compounds, and they supplied the material for in vitro competition binding assays . Both natural gallium natGa and the positron-emitting isotope 68Ga were used for labeling, with the 68Ga-labeled tracers produced in 27-57% decay-corrected radiochemical yield and with radiochemical purity above 95%.
Binding affinity separated the three compounds more sharply than the chemistry did. Ga-SP01011 had a Ki of 2.79 ± 0.77 nM, Ga-SP01010 was close at 4.29 ± 0.71 nM, and Ga-SP01022 was substantially weaker at 36.7 ± 5.11 nM. Low nanomolar affinity is what a useful GRPR ligand requires, and two of the three analogs cleared that bar comfortably.
In vivo, the ordering did not simply track affinity. 68Ga Ga-SP01011 showed the highest tumor uptake at 9.63 ± 1.07%ID/g, followed by 68Ga Ga-SP01022 at 4.17 ± 1.15%ID/g and 68Ga Ga-SP01010 at 3.98 ± 0.40%ID/g. Ga-SP01010 and Ga-SP01011 had comparable binding affinities, yet their tracers differed by more than a factor of two in tumor uptake. Whether that gap is statistically significant cannot be determined from the paper, which does not state animal numbers or significance testing.
Pancreas uptake, the property the study set out to fix, fell across the board. The three derivatives ranged from 0.83 to 4.96%ID/g, a reduction of roughly 80-97% relative to the parent, and all three tracers enabled clear visualization of PC-3 tumor xenografts on PET. The design objective was therefore met before any optimization of dose or imaging schedule.
The study combined synthesis, labeling, in vitro binding, and in vivo imaging and biodistribution in PC-3 tumor-bearing mice , with all measurements performed at 1 h post-injection. The endpoints were:
The single time point is both the strength and the limit of the design. At 1 h, a tracer must have cleared blood and nontarget tissue enough to produce contrast, so the measurement is a practical test of early imageability. But slow-clearing tracers can look deceptively poor at early times and better later, and fast-clearing ones can be gone before their peak. The study establishes that 68Ga Ga-SP01011 produces clear tumor images and low pancreas signal at that one moment. It does not establish when peak tumor uptake occurs, how quickly the tracer washes out, or what the optimal imaging window would be in patients.
Nor does the design support claims about safety. No sample size is reported, so the precision of the mean uptake values is unknown. No dosimetry, toxicity, or human data are reported. PC-3 is a standard model for this receptor: it is a prostate cancer line with high GRPR expression, and GRPR is overexpressed in several malignancies. But a single xenograft model cannot capture the range of receptor densities, vascularity, and clearance behavior across tumor types.
What the design can do is rank the three derivatives against the parent under identical conditions and identify a lead for further work. That is exactly what a structure-activity optimization campaign needs before committing to larger and more costly studies. 68Ga Ga-SP01011 earns that next step, but only that next step.
GRPR is a G protein-coupled receptor whose natural ligand, gastrin-releasing peptide, is the mammalian counterpart of the amphibian peptide bombesin. The receptor is overexpressed in several malignancies, and it is considered an attractive target for imaging and radioligand therapy. That combination of tumor expression and an established biology is why a long line of bombesin-like peptides has been developed as radiotracers.
Peptide radiotracers directed at GRPR work by receptor-mediated binding and internalization. The peptide portion docks on the receptor at the tumor cell surface, the chelator holds the radiometal in place, and once bound, the receptor-peptide complex is taken into the cell, trapping the signal within the tumor. The same mechanism that makes the tracer visible in tumors makes physiologic expression visible too, and the pancreas is the normal organ with the most conspicuous GRPR expression. A GRPR tracer that cannot separate tumor from pancreas will be handicapped in the abdomen, and high pancreatic signal also adds to the radiation burden.
The AA14 modification changed that equation. Replacing the piperidine moiety at AA14 with three different six-membered ring-containing groups reduced pancreas uptake in every case while preserving or improving tumor uptake. The most plausible reading is that the pancreatic background and the tumor signal are governed by partly separable molecular determinants: the changes that suppressed pancreatic retention did not necessarily cost tumor binding, and in the case of SP01011 they improved it.
The data do not say why. The exact structural differences among SP01010, SP01011, and SP01022 are not described in the paper, and competition binding assays measure equilibrium affinity, not internalization rate or metabolic stability, which often drive in vivo uptake differences. What the study shows is that AA14 is a sensitive handle on pharmacokinetics in this scaffold, a fact worth knowing for anyone designing around it.
For peptide researchers, the study is a working example of single-position structure-activity optimization. One substitution separated a tracer with 3.98 ± 0.40%ID/g tumor uptake from one with 9.63 ± 1.07%ID/g, and all three substitutions collapsed pancreas signal from 24.8 ± 1.77%ID/g to a maximum of 4.96%ID/g. Positions that are not essential for receptor binding but shape pharmacokinetics are prime sites for this kind of scan, and AA14 now looks like exactly such a position in this backbone.
For clinicians, the practical promise is contrast. A GRPR PET tracer with low pancreas uptake could improve detection of GRPR-expressing lesions and make readings in the upper abdomen more reliable. But the clinical question is not whether the tracer works in mice; it is whether the mouse profile survives human physiology, where receptor density, blood clearance, and metabolism differ. That question is unanswered.
For the supply chain, the chemistry is encouraging. Solid-phase synthesis produced all three analogs in 39-51% yield, the gallium-complexed standards in 69-82% yield, and the 68Ga-labeled tracers in 27-57% decay-corrected yield with radiochemical purity above 95%. 68Ga is available from generators in most nuclear medicine departments, so the labeling approach fits existing infrastructure. These numbers do not guarantee clinical production, but they describe a compound that is straightforward to make and label.
There is also a theranostic question embedded in the result. GRPR is considered an attractive target for radioligand therapy as well as imaging, and a scaffold with high tumor uptake and low pancreas retention would be attractive in both roles. Whether SP01011 can carry a therapeutic isotope such as 177Lu, and whether the low pancreas uptake would translate into reduced pancreatic dose, is untested.
The biggest gap is clinical. Every quantitative result in this study comes from PC-3 tumor-bearing mice, and no human data are reported. Peptide radiotracers have a history of mouse biodistributions that did not predict human ones, so the tumor-to-pancreas profile of 68Ga Ga-SP01011 will need to be re-established in patients.
Several specific questions would settle whether the lead is real. First, the paper does not state animal numbers or statistical comparisons, so the reliability of the uptake ranking is unknown; a repeat study with explicit group sizes would firm it up. Second, measurements at only 1 h post-injection leave the kinetics unknown. Later time points would show whether tumor uptake peaks, plateaus, or declines, and would define the imaging window. Third, dosimetry and a full normal-organ profile were not reported, and both are needed before any human use.
Structural detail is also missing. The exact differences among SP01010, SP01011, and SP01022 are not described, which limits what can be learned from the affinity and biodistribution data. Knowing which ring system improves affinity and which suppresses pancreas uptake would let chemists generalize the finding beyond this single scaffold.
Finally, 68Ga Ga-SP01011 has not been compared head-to-head with other GRPR-targeting PET tracers, so its tumor-to-background ratios relative to the existing field are unknown. A head-to-head study in the same animals, with the same acquisition and analysis, would be the decisive test. The current study establishes 68Ga Ga-SP01011 as a credible lead with a clear mechanism of improvement. Everything after this point depends on evidence it does not yet have.
Related reading: Handling Guide for Lyophilised MT-2: Identity, Storage, Traceability, Imperial Peptides UK sets MT-2 documentation standard for research supply, Retatrutide hits 25-30% weight loss as GLP-1 risks and benefits widen, GLP-1 therapies show cardiovascular benefit beyond glucose control.